<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="8768">Rabeprazole</z:chebi> is a <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> (<z:chebi fb="4" ids="53266">PPI</z:chebi>) presenting a very advantageous pharmacodynamic and pharmacokinetic profile over older <z:chebi fb="4" ids="53266">PPIs</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>In particular, this drug has a very fast <z:hpo ids='HP_0003674'>onset</z:hpo> of action, due to a short activation time and a very high pKa, and may therefore be defined as a 'second generation' <z:chebi fb="4" ids="53266">PPI</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this article is to provide an update on the pharmacology and clinical profile of <z:chebi fb="0" ids="8768">rabeprazole</z:chebi> and its use in acid-related disorders, with a particular focus on its role in <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo>; in the treatment and prevention of duodenal and <z:hpo ids='HP_0002592'>gastric ulcers</z:hpo> and <z:hpo ids='HP_0002044'>Zollinger-Ellison syndrome</z:hpo>; in the therapy of the extraesophageal manifestations of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (in particular the respiratory and ear, nose and throat ones); and in the eradication of Helicobacter pylori </plain></SENT>
</text></document>